Guangdong Marubi Biotechnology (603983) Fundamentals 2026 — P/E 57.1x, Revenue Analysis | SniperIQ
Guangdong Marubi Biotechnology (603983) is a CN-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥12.1B, trading at ¥30.17 on the SHH. This SniperIQ fundamentals page covers Guangdong Marubi Biotechnology's valuation (P/E 57.1x, P/B 3.5x), profitability (net margin 6.1%), revenue (¥3.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangdong Marubi Biotechnology's market cap?
Guangdong Marubi Biotechnology (603983) has a market capitalization of approximately ¥12.1B, trading at ¥30.17 on the SHH. Market cap moves with the live share price.
What is Guangdong Marubi Biotechnology's P/E ratio?
Guangdong Marubi Biotechnology's trailing twelve-month P/E ratio is 57.1x, with a price-to-book (P/B) of 3.5x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Guangdong Marubi Biotechnology?
Guangdong Marubi Biotechnology runs a net profit margin of 6.1%, a gross margin of 73.7%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangdong Marubi Biotechnology generate?
Guangdong Marubi Biotechnology reported revenue of ¥3.5B for fiscal year 2025, with net income of ¥247M and earnings per share (EPS) of 0.62. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangdong Marubi Biotechnology pay a dividend?
Guangdong Marubi Biotechnology offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangdong Marubi Biotechnology financially healthy?
Guangdong Marubi Biotechnology carries a debt-to-equity ratio of 0.14x and a current ratio of 1.97x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangdong Marubi Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangdong Marubi Biotechnology (603983) the key facts are: market cap ¥12.1B, P/E 57.1x, revenue ¥3.5B, 52-week range 21.2-45.76. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Guangdong Marubi Biotechnology's full fundamentals live
Get Guangdong Marubi Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.